Suchergebnisse - "Kazandjian, Dickran"

PubPharm (5)

1

Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma

enthalten in: The oncologist | 2021

von Kazandjian, D. | Dew, A. | Hill, E. | +19

2

Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma

enthalten in: The oncologist | 2021

von Kazandjian, D. | Dew, A. | Hill, E. | +19

3

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer

enthalten in: The oncologist | 2016

von Kazandjian, D. | Blumenthal, G. | Luo, L. | +4

4

FDA Approval Summary : Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

enthalten in: The oncologist | 2016

von Kazandjian, D. | Suzman, D. | Blumenthal, G. | +5

CommentIn: Oncologist. 2016 Dec;21(12 ):e3. - PMID 27864576

5

FDA approval summary : crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements

enthalten in: The oncologist | 2014

von Kazandjian, D. | Blumenthal, G. | Chen, H. | +5

1
[1]